Eciruciclib

CAS No. 1868086-40-1

Eciruciclib( —— )

Catalog No. M28496 CAS No. 1868086-40-1

Eciruciclib is an inhibitor of CDK with antitumor properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 312 Get Quote
10MG 500 Get Quote
25MG 807 Get Quote
50MG 1107 Get Quote
100MG 1485 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Eciruciclib
  • Note
    Research use only, not for human use.
  • Brief Description
    Eciruciclib is an inhibitor of CDK with antitumor properties.
  • Description
    Eciruciclib is an inhibitor of CDK with antitumor properties.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1868086-40-1
  • Formula Weight
    488.6
  • Molecular Formula
    C27H33FN8
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 2 mg/mL (4.09 mM)
  • SMILES
    CC(C1=C2C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=CC2=NN1C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • TCS 1102

    TCS 1102 is an effective, dual orexin receptor antagonist (Ki: 0.2/3 nM for OX2/1 receptors).

  • BSJ-4-116

    BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM.?It downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation).

  • (R)-CR8

    (R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.